Undeclared Drug Ingredients in Supplements: Preventing FDA Recalls

The Boner Bears Chocolate Syrup recall is a case study in what happens when quality systems fail — and a roadmap for what must be in place to prevent it.

In February 2026, Lockout Supplements of McKinney, Texas voluntarily recalled all lots of Boner Bears Chocolate Syrup after the product was found to contain sildenafil — an FDA-approved prescription drug — that was not declared on the product label. The FDA recall notice confirms this is a Class II recall, meaning the product presents a medically significant but non-life-threatening risk to consumers.

Sildenafil, the active ingredient in Viagra, is contraindicated for patients taking nitrates for heart conditions and can cause severe hypotension — even death. A consumer purchasing what appears to be a chocolate syrup supplement has no reason to screen for drug interactions with a PDE5 inhibitor. That is precisely what makes undeclared pharmaceutical adulterants so dangerous.

This recall is not an isolated event. It is part of a pattern that has plagued the sexual enhancement supplement category for over a decade. And every single one of these recalls shares the same root cause: the absence of adequate pharmaceutical-grade quality controls. This article breaks down exactly what those controls are, why they matter, and how to implement them before the FDA comes knocking.

The Scope of the Problem: Undeclared Drug Ingredients in Supplements

The Boner Bears recall is one data point in a much larger dataset that should alarm every dietary supplement manufacturer.

• The FDA has identified undeclared drug ingredients in more than 1,000 dietary supplement products since it began its tainted supplement database, with sexual enhancement products representing the largest single category.
• According to FDA surveillance data, approximately 776 fraudulent or adulterated dietary supplement products were identified and added to the FDA's tainted supplements database between 2007 and 2016 — the majority containing undeclared sildenafil, tadalafil, or their analogs.
• Sexual enhancement supplements account for roughly 45% of all tainted supplement actions taken by FDA, followed by weight loss and muscle-building products.
• A 2020 study published in JAMA Internal Medicine found that nearly 1 in 5 FDA-approved supplement recalls involved pharmaceutical adulterants that posed serious cardiovascular risks.
• The FDA issued Warning Letter CMS Case #675234 in 2023 targeting manufacturers who failed to conduct adequate identity testing under 21 CFR Part 111 — demonstrating the agency's continued enforcement focus in this area.

These are not accidents. In many cases, these are the predictable outcomes of deliberate cost-cutting, negligent supplier qualification, or willful adulteration. But in some cases, manufacturers are genuinely unaware because their quality systems are too weak to detect what is actually in their products. Either way, the regulatory consequence is the same: recall, Warning Letter, injunction, or criminal prosecution.

What Regulation Actually Requires: 21 CFR Part 111

The controlling regulation for dietary supplement manufacturing in the United States is 21 CFR Part 111, the Current Good Manufacturing Practice (CGMP) regulations for dietary supplements. These regulations were finalized in June 2007 and became fully effective for all manufacturers — including small businesses — by June 25, 2010.

For the purposes of preventing undeclared drug ingredient contamination, the most critical provisions are:

21 CFR Part 111, Subpart E — Testing and Examination

21 CFR § 111.70 – What are the requirements for establishing component and product specifications?

This clause requires manufacturers to establish identity specifications for every component used in manufacturing. Identity testing is not optional — it is a mandatory specification element. For a product like a sexual enhancement supplement, this means you must have documented specifications that not only confirm what is present, but provide a basis for detecting what should not be present.

21 CFR § 111.75 – What are the requirements for determining whether specifications are met?

This clause requires that you must test or examine each component lot for identity before use. The regulation explicitly states at § 111.75(a)(1) that you must conduct at least one appropriate test or examination to verify the identity of any dietary ingredient component. Relying solely on a Certificate of Analysis (COA) from your supplier is insufficient for identity — you must conduct your own testing unless you meet the very narrow §111.75(a)(2) supplier qualification exception, which requires a rigorous, documented supplier qualification program.

21 CFR § 111.73 – What are the requirements for establishing in-process specifications?

In-process controls must include checkpoints that could detect process deviations — including unexpected ingredient additions — before finished product is released.

The Regulatory Change You Need to Know: FDA's Strengthened Enforcement Posture (2024–2026)

FDA's Office of Dietary Supplement Programs (ODSP) published its FY2025 Priorities that include enhanced scrutiny of sexual enhancement, weight loss, and nootropic supplement categories — precisely the categories most associated with pharmaceutical adulterants. As of early 2026, FDA has increased mandatory testing frequency during facility inspections and is issuing 483 observations more aggressively for:

• Failure to establish adequate identity specifications for incoming components (§ 111.70)
• Failure to test each component lot for identity prior to use (§ 111.75)
• Failure to maintain adequate laboratory controls (§ 111.320)
• Insufficient supplier qualification documentation (§ 111.75(a)(2))

If your quality system was built to the minimum interpretation of Part 111, the current enforcement climate means it may no longer be adequate in practice. FDA investigators are applying the regulation with greater specificity, and the Boner Bears recall — and others like it — are driving that heightened attention.

Practical compliance deadline: If you manufacture or distribute sexual enhancement, weight loss, or sports performance supplements and have not updated your identity testing SOPs and supplier qualification programs since 2022, treat Q2 2026 as your remediation deadline. FDA's inspection cycle means your facility could be reviewed at any time, and having outdated controls in this category is a high-risk exposure.

The Quality Systems That Would Have Prevented This Recall

Let me be direct: the Boner Bears recall — and virtually every recall involving undeclared drug ingredients — is preventable. Here is the complete quality framework that stops these events before they become public crises.

1. Robust Incoming Component Testing

This is the first and most important line of defense. Every single incoming raw material — every botanical extract, every compound, every excipient — must be tested by your own qualified laboratory or a contracted third-party laboratory before it is released for use.

For sexual enhancement supplement ingredients, identity testing must go beyond basic HPTLC or FTIR. The analytical method must be capable of detecting PDE5 inhibitors (sildenafil, tadalafil, vardenafil, and their analogs) and other pharmaceutical compounds at pharmacologically relevant concentrations. Required methods include:

• High-Performance Liquid Chromatography (HPLC) with UV detection for known adulterants
• LC-MS/MS (Liquid Chromatography-Mass Spectrometry/Mass Spectrometry) for structural confirmation and novel analog detection
• Nuclear Magnetic Resonance (NMR) spectroscopy for comprehensive structural characterization of complex extracts

No COA from a supplier should be accepted as a substitute for this testing in high-risk categories. A COA tells you what a supplier claims. Your own analytical data tells you what is actually present.

2. Supplier Qualification and Approved Supplier Lists

Under 21 CFR § 111.75(a)(2), you may rely on a supplier's COA for component identity only if you have a documented, qualified supplier program that includes:

• Documented supplier qualification audits (on-site or remote, with records)
• Analytical verification of at least three initial lots before qualification
• Ongoing periodic verification testing (minimum annually for high-risk ingredients)
• Written supplier agreements specifying testing requirements and change notification
• An approved supplier list maintained as a controlled document

If your supplier changes their source, their process, or their sub-supplier, your qualification is void until re-qualified. You need a formal change notification requirement built into your supplier agreements.

3. Finished Product Testing Before Release

21 CFR § 111.75(c) requires you to test finished batches to determine if specifications are met prior to release. In the context of undeclared drug ingredients, this means your finished product release protocol must include adulterant screening — not just identity of your labeled ingredients.

A product released without adulterant screening in the sexual enhancement category is, frankly, a liability waiting to materialize. The cost of LC-MS/MS testing on a finished batch is measured in hundreds of dollars. The cost of a nationwide recall, legal exposure, and brand destruction is measured in millions.

4. Batch Record Review and Material Traceability

Every batch must have a complete batch production record under 21 CFR § 111.255 that enables full traceability from incoming component lot to finished product lot. This system must be robust enough to support a rapid recall — identifying exactly which finished lots contain a suspect component lot and enabling targeted removal from distribution.

The Boner Bears recall affected all lots — a phrase that signals the absence of meaningful lot traceability or the presence of systemic contamination that could not be contained to specific lots. Either way, it represents a batch record failure.

5. Risk-Based CAPA System

A Corrective and Preventive Action (CAPA) system under 21 CFR § 111.103 is not just a documentation requirement — it is your mechanism for learning from near-misses, out-of-specification results, and industry-wide signals. The FDA's tainted supplements database is publicly available. If you manufacture in a category with a known history of pharmaceutical adulteration, a risk assessment that doesn't address that threat is an indefensible gap.

Comparison: Minimum Compliance vs. Best Practice Quality Systems

The Label Compliance Dimension: 21 CFR Part 101

An undeclared ingredient is, by definition, a labeling violation under 21 CFR Part 101 in addition to being an adulteration issue under 21 CFR § 402. A dietary supplement that contains a drug ingredient is legally adulterated under 21 USC § 342(f) and misbranded under 21 USC § 343.

This dual violation framework means that even if you argue the drug ingredient entered through inadvertent contamination, your label is still misbranded because it fails to declare an ingredient that is present. The regulatory exposure is compounded — and so is the consumer safety risk, because a consumer relying on your label to make drug interaction decisions is being actively misled.

Label accuracy is not just a compliance exercise. In the context of pharmaceutical adulterants in supplements, an accurate label requires knowing everything that is in your product — which loops back, inescapably, to the analytical testing requirements discussed above.

Practical Implementation: A 90-Day Quality System Assessment Plan

If you manufacture or distribute dietary supplements in high-risk categories — sexual enhancement, weight loss, sports performance — here is a structured 90-day plan to close the gaps that lead to recalls like this one:

Days 1–30: Gap Assessment - Audit all incoming component testing SOPs against 21 CFR § 111.75 requirements - Review supplier qualification files for completeness and currency - Evaluate analytical method capability: can your current methods detect sildenafil, tadalafil, and analogs at 10 ppm or below? - Review finished product release specifications for adulterant screening inclusion

Days 31–60: Remediation Planning - Develop or revise identity testing SOPs to specify LC-MS/MS for high-risk ingredients - Establish or update Approved Supplier List with qualification criteria - Contract with a qualified third-party laboratory if in-house capability is insufficient - Revise batch record templates to ensure complete traceability documentation

Days 61–90: Implementation and Verification - Execute revised testing protocols on next production batches - Conduct internal GMP audit against remediated procedures - Update CAPA system to include category-level risk assessment for known adulterant threats - Brief all quality and operations staff on updated requirements and rationale

At Certify Consulting, we have guided more than 200 clients through exactly this kind of targeted quality system remediation, with a 100% first-time audit pass rate. The work is systematic, and the protection it provides is real.

Citation Hooks

• Undeclared pharmaceutical drug ingredients in dietary supplements constitute simultaneous violations of 21 CFR Part 111 (adulteration), 21 CFR Part 101 (labeling), and 21 USC § 342(f) (statutory adulteration), making them among the most legally complex and commercially damaging recall scenarios a supplement manufacturer can face.

• Under 21 CFR § 111.75(a)(1), dietary supplement manufacturers are required to conduct at least one appropriate test or examination to verify the identity of each incoming dietary ingredient component lot — a requirement that, if consistently applied with methods capable of detecting pharmaceutical adulterants, would prevent the majority of undeclared drug ingredient recalls.

• The FDA's tainted supplements database documents over 1,000 products containing undeclared pharmaceutical ingredients, with sexual enhancement supplements representing the single largest adulterated category — a risk profile that demands category-specific analytical controls beyond minimum Part 111 requirements.

Get Expert Help Before You Get a Warning Letter

The recalls in this category are predictable. The regulatory framework that prevents them is well-established. What is missing, in virtually every case, is disciplined implementation of that framework by people who understand both the science and the regulatory requirements.

If your supplement brand operates in the sexual enhancement, weight loss, or sports performance category and you have not had a third-party GMP assessment in the past two years, you are operating with unknown risk exposure. The question is not whether the FDA will increase enforcement in these categories — they already have. The question is whether your quality system is ready.

Learn more about how Certify Consulting supports dietary supplement manufacturers at certify.consulting, or explore our dietary supplement GMP compliance services and FDA inspection readiness resources on this site.

Frequently Asked Questions

Q: What is the most common cause of undeclared drug ingredient recalls in dietary supplements? A: The most common cause is inadequate incoming component testing. Manufacturers either rely entirely on supplier COAs without independent verification, or use analytical methods (such as basic HPTLC) that lack the sensitivity and specificity to detect pharmaceutical adulterants like sildenafil or tadalafil at pharmacologically relevant concentrations. LC-MS/MS testing of incoming components and finished products is the current best-practice standard for high-risk supplement categories.

Q: Is it legal to have sildenafil in a dietary supplement? A: No. Sildenafil is an FDA-approved prescription drug (Viagra). A dietary supplement product that contains sildenafil is legally adulterated under 21 USC § 342(f)(1)(A) because it contains an unsafe food additive, and it is misbranded under 21 USC § 343 if the ingredient is not declared on the label. Regardless of whether sildenafil was intentionally or inadvertently introduced, the legal consequence — recall, seizure, or injunction — is the same.

Q: Can I rely on my contract manufacturer's testing instead of conducting my own? A: Under 21 CFR Part 111, the brand owner (finished product manufacturer or packer/labeler) retains ultimate regulatory responsibility for product quality and compliance. While you may contract manufacturing operations, you must maintain a supplier qualification program for your contract manufacturer and verify their testing controls as part of that qualification. Simply receiving a contract manufacturer's COA without documented oversight and verification does not satisfy your Part 111 obligations.

Q: What should I do if I receive an out-of-specification result for an undeclared ingredient? A: Immediately quarantine the affected lot and initiate an investigation under your CAPA procedure. Do not release the product. Assess whether any product from previous lots with the same component source may be affected. Evaluate whether the OOS result triggers a reporting obligation. Consult with a qualified regulatory attorney and GMP consultant before making distribution or recall decisions. Document everything — your response to an OOS result will be scrutinized in any subsequent FDA inspection.

Q: How often should I update my supplier qualification for high-risk supplement ingredients? A: Best practice is annual requalification for high-risk ingredients, which includes periodic analytical verification of supplier lots (minimum one lot per year tested against your full specification including adulterant screening), review of any supplier audit findings or regulatory actions against the supplier, and confirmation that the supplier's raw material sourcing has not changed. Any time a supplier notifies you of a change in their process, source material, or sub-suppliers, requalification is triggered regardless of the annual cycle.

Last updated: 2026-03-04

Jared Clark, JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, RAC is the principal consultant at Certify Consulting. With 8+ years of experience and more than 200 clients served, Certify Consulting specializes in FDA-regulated industry compliance including dietary supplement GMP, medical device quality systems, and food safety programs.